Ariel Weinberger

Dr. Ariel Weinberger is the CEO & Founder of Autonomous Therapeutics (Autonomous), and has led the company since its founding in 2017. Ari started the company out of a single desk in the Brooklyn Navy Yard, incubated the company at Johnson & Johnson’s JLABS facility in New York City, and now leads over 20 employees in a state-of-the-art 20,000 square foot facility in Rockville, MD. Ari and the team have developed multiple first-in-class therapeutic technologies from COVID-19 to RSV, including a new class of RNA therapeutics. Ari and Autonomous have raised millions of dollars in non-dilutive and venture capital funding to develop Autonomous’ portfolio.

Ari completed his Ph.D. in Biophysics at the University of California, Berkeley where he was an NDSEG fellow, and subsequently completed his postdoctoral training as a NIH Ruth L. Kirschstein Fellow at Harvard. Prior to founding Autonomous, Ari was a Principal Investigator and Wyss Institute Technology Development Fellow at Harvard Medical School.